Radiotherapy for laryngeal squamous cell carcinoma: Current standards

Expert Review of Anticancer Therapy

Volumn 10, Issue 9, 2010, Pages 1461-1469

  Dirix, Piet ^a   Lambrecht, Maarten ^a   Nuyts, Sandra ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

chemotherapy; IMRT; laryngeal cancer; radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; TRANSFORMING GROWTH FACTOR ALPHA;

CANCER LOCALIZATION; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG SENSITIVITY; DYSPHAGIA; HEAD AND NECK CARCINOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LARYNGECTOMY; LARYNX CARCINOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PROTEIN EXPRESSION; QUALITY OF LIFE; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIOSENSITIVITY; REVIEW; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; LARYNGEAL NEOPLASMS; LARYNX; STANDARD OF CARE; TREATMENT OUTCOME;

EID: 77956712159     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.110     Document Type: Review

References (75)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
2. Spitz MR. Epidemiology and risk factors for head and neck cancer. Semin. Oncol. 21, 281-288 (1994).
3. Argiris A, Eng C. Epidemiology, staging, and screening of head and neck cancer. Cancer Treat. Res. 114, 15-60 (2003).
4. Hoffman HT, Porter K, Karnell LH et al Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 116, 1-13 (2006).
5. Tamura Y, Tanaka S, Asato R et al Therapeutic outcomes of laryngeal cancer at Kyoto, University Hospital for 10 years. Acta Otolaryngol. Suppl. 557, 62-65 (2007).
6. Pfster DG, Laurie SA, Weinstein GS et al American Society of Clinical Oncology clinical practice guidelines for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J. Clin. Oncol. 24, 3693-3704 (2006).
7. Olsen KD. Re-examining the treatment of advanced laryngeal cancer. Head Neck 32, 1-7 (2010).
8. Holsinger FC, Nussenbaum B, Nakayama M et al. Current concepts and new horizons in conservation laryngeal surgery: an important part of multidisciplinary care. Head Neck 32, 656-665 (2010).
9. Forastiere AA. Larynx preservation and survival trends: should there be concern? Head Neck 32, 14-17 (2010).
10. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N. Engl. J. Med. 324, 1685-1690 (1991).
11. Chen AY, Schrag N, Hao Y et al. Changes in treatment of advanced laryngeal cancer 1985-2001. Otolaryngol. Head Neck Surg. 135, 831-837 (2006).
12. Silver CE, Beitler JJ, Shaha AR, Rinalod A, Ferlito A. Current trends in initial management of laryngeal cancer: the declining use of open surgery. Eur. Arch. Otorhinolaryngol. 266, 1333-1352 (2009).
13. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer Phase III trial. EORTC Head and Neck Cancer Cooperative Group. J. Natl Cancer Inst. 88, 890-899 (1996).
14. Nguyen LN, Ang KK. Radiotherapy for cancer of the head and neck: altered fractionation regimens. Lancet Oncol. 3, 693-701 (2002).
15. Van Den Bogaert W, Van Der Leest A, Rijnders A et al. Does tumour control decrease by prolonging overall treatment time or interrupting treatment in laryngeal cancer? Radiother. Oncol. 36, 177-182 (1995).
16. Overgaard J, Hansen HS, Specht L et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 & 7 randomised controlled trial. Lancet 362, 933-940 (2003).
17. Overgaard J, Mohanti BK, Begum N et al. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. Lancet Oncol. 11(6), 553-560 (2010).
18. Dische S, Saunders M, Barrett A et al. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother. Oncol. 44, 123-136 (1997).
19. Fu KK, Clery M, Ang KK et al. Randomized Phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09. Int. J. Radiat. Oncol. Biol. Phys. 32, 589-597 (1995).
20. Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation therapy for head and neck squamous cell carcinomas: frst report of RTOG 90-03. Int. J. Radiat. Oncol. Biol. Phys. 48, 7-16 (2000).
21. Bourhis J, Overgaard J, Audry H et al. Hyper fractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368, 843-1584 (2006).
22. Forastiere AA, Goepfert H, Maor M et al Concurrent chemoradiotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med. 349, 2091-2098 (2003).
23. Forastiere AA, Maor M, Weber R et al Long-term results of Intergroup RTOG 91-111: a Phase III trial to preserve the larynx-induction cisplatin/5FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. Proc. Am. Soc. Clin. Oncol. 24 (2006) (Abstract 5517).
24. Pignon JP, Bourhis J, Domenge C, Designe L; on behalf of the MACH-NC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355, 949-955 (2000).
25. Bourhis J, Amand C, Pignon JP; on behalf of the MACH-NC Collaborative Group. Update of the MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy J. Clin. Oncol. 22(14S), 5505 (2004).
26. Pignon JP, le Maître A, Maillard E, Bourhis J; on behalf of the MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother. Oncol. 92, 4-14 (2009).
27. Jeremic B, Milicic B, Dagovic A et al. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, non-metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 22, 3540-3548 (2004).
28. Hoebers FJP, Heemsbergen W, Balm AJM et al. Concurrent chemoradiation with daily low dose cisplatin for advanced stage head and neck carcinoma. Radiother. Oncol. 85, 42-47 (2007).
29. Bourhis J, Sire C, Lapeyre M et al Accelerated radiotherapy and/or concomitant chemotherapy in locally advanced head and neck squamous cell carcinoma: results of a GORTEC randomized trial. Radiother. Oncol. 90, S6-S7 (2009).
30. Nuyts S, Dirix P, Hermans R et al. Early experience with a hybrid accelerated radiotherapy schedule for locally advanced head and neck cancer. Head Neck 29, 720-730 (2007).
31. Nuyts S, Dirix P, Clement PMJ et al Impact of adding concomitant chemotherapy to hyper fractionated accelerated radiotherapy for advanced head and neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 73, 1088-1095 (2009).
32. Laccourreye O, Bassot V, Brasnu D, Laccourreye H. Chemotherapy combined with conservation surgery in the treatment of early larynx cancer. Curr. Opin. Oncol. 11, 200-203 (1999).
33. Sessions DG, Lenox J, Spector GJ et al Management of T3N0M0 glottic carcinoma: therapeutic outcomes. Laryngoscope 112, 1281-1288 (2002).
34. Hinerman RW, Mendenhall WM, Morris CG et al. T3 and T4 true vocal cord squamous carcinomas treated with external beam irradiation: a single institution's 35-year experience. Am. J. Clin. Oncol. 30, 181-185 (2007).
35. Becker M. Neoplastic invasion of laryngeal cartilage: radiologic diagnosis and therapeutic implications. Eur. J. Radiol. 33, 216-229 (2000).
36. Samant S, Robbins KT, Kumar P et al. Bone or cartilage invasion by advanced head and neck cancer: intra-arterial supradose cisplatin chemotherapy and concomitant radiotherapy for organ preservation. Arch. Otolaryngol. Head Neck Surg. 127, 1451-1456 (2001).
37. Rodriguez CP, Adelstein DJ, Rybicki LA et al. Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapy. Head Neck 30, 1535-1542 (2008).
38. Knab BR, Salama JK, Solanki A et al. Functional organ preservation with defnitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Ann. Oncol. 19, 1650-1654 (2008).
39. Worden FP, Moyer J, Lee JS et al. Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. Laryngoscope 199, 1510-1517 (2009).
40. Mendenhall WM, Mancuso AA, Hinerman RW et al. Multidisciplinary management of laryngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 69, S12-S14 (2007).
41. Ang KK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 62, 7350-7356 (2002).
42. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578 (2006).
43. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a Phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11, 21-28 (2010).
44. Curran D, Giralt J, Harari PM et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J. Clin. Oncol. 25, 2191-2197 (2007).
45. Adelstein DJ, Li Y, Adams GL et al An intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patienst with unresectable squamous cell head and neck cancer. J. Clin. Oncol. 21, 92-98 (2003).
46. Lefebvre JL, Rolland F, Tesselaar M et al Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J. Natl Cancer Inst. 101, 142-452 (2009).
47. List MA, Stracks J, Colangelo L et al. How do head and neck cancer patients prioritize treatment outcomes before initiating treatment? J. Clin. Oncol. 18, 877-884 (2000).
48. Machtay M, Moughan J, Trotti A et al Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J. Clin. Oncol. 26, 3582-3589 (2008).
49. Dirix P, Nuyts S, Van Den Bogaert W. Radiation-induced xerostomia in patients with head and neck cancer: a literature review. Cancer 107, 2525-2534 (2006).
50. Platteaux N, Dirix P, Dejaeger E, Nuyts S. Dysphagia in head and neck cancer patients treated with chemoradiotherapy Dysphagia 25(2), 139-152 (2009).
51. Eisbruch A, Lyden T, Bradford CR et al Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head and neck cancer. Int. J. Radiat. Oncol. Biol Phys. 53, 23-28 (2002).
52. Nguyen NP, Frank C, Moltz CC et al Impact of dysphagia on quality of life after treatment of head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 61, 772-778 (2005).
53. Caudell JJ, Schaner PE, Meredith RF et al. Factors associated with long-term dysphagia after defnitive radiotherapy for locally advanced head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 73, 410-415 (2009).
54. Langendijk JA, Doornaert P, Rietveld DHF et al. A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. Radiother. Oncol. 90, 189-195 (2009).
55. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM et al. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J. Clin. Oncol. 26, 3770-3776 (2008).
56. Tsao AS, Garden AS, Kies MS et al. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J. Clin. Oncol. 24, 4163-4169 (2006).
57. Dirix P, Nuyts S. Evidence-based organ-sparing radiotherapy in head and neck cancer. Lancet Oncol. 11, 85-91 (2010).
58. Lambert L, Fortin B, Soulières D et al. Organ preservation with concurrent chemoradiation for advanced laryngeal cancer: are we succeeding? Int. J. Radiat. Oncol. Biol. Phys. 76, 398-402 (2009).
59. Terrell JE, Fisher SG, Wolf GT. Long-term quality of life after treatment of laryngeal cancer. Arch. Otolaryngol. Head Neck Surg. 124, 964-971 (1998).
60. Hanna E, Sherman A, Cash D et al. Quality of life after treatment for patients following total laryngectomy versus chemoradiation for laryngeal preservation. Arch. Otolaryngol. Head Neck Surg. 129, 733-738 (2003).
61. Fung K, Lyden TH, Lee J et al. Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer. Int. J. Radiat. Oncol. Biol. Phys. 63, 1395-1399 (2005).
62. Veldeman L, Madani I, Hulstaert F et al. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol. 9, 367-375 (2008).
63. Nutting C, A'Hern R, Rogers MS et al.; on behalf of the PARSPORT Trial Management Group. First results of a Phase III multicenter randomized controlled trial of intensity modulated versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). J. Clin. Oncol. 27(18 Suppl.) (2009) (Abstract LBA6006).
64. Eisbruch A, Levendag PC, Feng FY et al. Can IMRT or brachytherapy reduce dysphagia associated with chemoradiotherapy of head and neck cancer? The Michigan and Rotterdam experiences. Int. J. Radiat. Oncol. Biol. Phys. 69, S40-S42 (2007).
65. Dirix P, Nuyts S. Value of intensity-modulated radiotherapy in stage IV head and neck squamous cellcarcinoma. Int. J. Radiat. Oncol. Biol. Phys. DOI: 10.1016/j.ijrobp.2009.10.018 (2010) (Epub ahead of print).
66. Paccagnella A, Orlando A, Marchiori C et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J. Natl Cancer Inst. 86, 265-272 (1994).
67. Domenge C, Hill C, Lefebvre JL et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs De la Tete et du Cou (GETTEC). Br J. Cancer 83, 1594-1598 (2000).
68. Urba S, Wolf G, Eisbruch A et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J. Clin. Oncol. 24, 593-598 (2006).
69. Posner MR, Glisson B, Frenette G et al. Multicenter Phase I-II trial of docetaxel, cisplatin, and fuorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J. Clin. Oncol. 19, 1096-1104 (2001).
70. Vermorken JB, Remenar E, Van Herpen C et al. Standard cisplatin/infusional 5-fuorouracil (PF) vs. docetaxel (T) plus PF (TPF) as neo-adjuvant chemotherapy for non-resectable locally advanced head and neck cancer (LAHNC): a Phase III of the EORTC head and neck cancer group (EORTC # 24971). J. Clin. Oncol. 22, S5508 (2004).
71. Hitt R, Lopez-Pousa A, Martinez-Trufero J et al. Phase III study comparing cisplatin plus fuorouracil to paclitaxel, cisplatin and fuorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J. Clin. Oncol. 23, 8636-8645 (2005).
72. Pointreau Y, Garaud P, Chapet S et al. Randomized trial of induction chemotherapy with cisplatin and 5-fuorouracil with or without docetaxel for larynx preservation. J. Natl Cancer Inst. 101, 498-506 (2009).
73. Hitt R, Grau J, Lopez-Pousa A et al. Final results of a randomized Phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as frst-line treatment of unresectable locally advanced head and neck cancer (LAHNC). J. Clin. Oncol. 27(15 Suppl.) (2009) (Abstract 6009).
74. Lefebvre J, Pointreau Y, Rolland F et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): preliminary results of the randomized Phase II TREMPLIN study. J. Clin. Oncol. 27(15 Suppl.) (2009) (Abstract 6010).
75. Haigentz M Jr, Silver CE, Hartl DM et al. Chemotherapy regimens and treatment protocols for laryngeal cancer. Expert Opin. Pharmacother. 11, 1305-1316 (2010).